188 related articles for article (PubMed ID: 27602116)
1. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.
Chen S; Li X; Chen R; Yin M; Zheng Q
Oncol Lett; 2016 Sep; 12(3):1868-1876. PubMed ID: 27602116
[TBL] [Abstract][Full Text] [Related]
2. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
3. Reovirus enhances cytotoxicity of natural killer cells against colorectal cancer via TLR3 pathway.
Long S; Gu Y; An Y; Lin X; Chen X; Wang X; Liao C; Ouyang W; Wang N; He Z; Zhao X
J Transl Med; 2021 May; 19(1):185. PubMed ID: 33933132
[TBL] [Abstract][Full Text] [Related]
4. A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.
Fujii R; Schlom J; Hodge JW
J Neurosurg; 2018 May; 128(5):1419-1427. PubMed ID: 28753113
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
[TBL] [Abstract][Full Text] [Related]
6. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
7. Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.
Veluchamy JP; Spanholtz J; Tordoir M; Thijssen VL; Heideman DA; Verheul HM; de Gruijl TD; van der Vliet HJ
PLoS One; 2016; 11(6):e0157830. PubMed ID: 27314237
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines.
Kurai J; Chikumi H; Hashimoto K; Yamaguchi K; Yamasaki A; Sako T; Touge H; Makino H; Takata M; Miyata M; Nakamoto M; Burioka N; Shimizu E
Clin Cancer Res; 2007 Mar; 13(5):1552-61. PubMed ID: 17332301
[TBL] [Abstract][Full Text] [Related]
9. IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients.
Roberti MP; Rocca YS; Amat M; Pampena MB; Loza J; Coló F; Fabiano V; Loza CM; Arriaga JM; Bianchini M; Barrio MM; Bravo AI; Domenichini E; Chacón R; Mordoh J; Levy EM
Breast Cancer Res Treat; 2012 Dec; 136(3):659-71. PubMed ID: 23065032
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
[TBL] [Abstract][Full Text] [Related]
11. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines.
Roda JM; Joshi T; Butchar JP; McAlees JW; Lehman A; Tridandapani S; Carson WE
Clin Cancer Res; 2007 Nov; 13(21):6419-28. PubMed ID: 17962339
[TBL] [Abstract][Full Text] [Related]
12.
Veluchamy JP; Lopez-Lastra S; Spanholtz J; Bohme F; Kok N; Heideman DA; Verheul HM; Di Santo JP; de Gruijl TD; van der Vliet HJ
Front Immunol; 2017; 8():87. PubMed ID: 28220124
[TBL] [Abstract][Full Text] [Related]
13. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
Patel D; Guo X; Ng S; Melchior M; Balderes P; Burtrum D; Persaud K; Luna X; Ludwig DL; Kang X
Hum Antibodies; 2010; 19(4):89-99. PubMed ID: 21178280
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the change in cetuximab-induced antibody-dependent cellular cytotoxicity activity of natural killer cells by steroid.
Kumai T; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Kobayashi H
Head Neck; 2016 Mar; 38(3):410-6. PubMed ID: 25352398
[TBL] [Abstract][Full Text] [Related]
15. IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.
McMichael EL; Jaime-Ramirez AC; Guenterberg KD; Luedke E; Atwal LS; Campbell AR; Hu Z; Tatum AS; Kondadasula SV; Mo X; Tridandapani S; Bloomston M; Ellison EC; Williams TM; Bekaii-Saab T; Carson WE
Clin Cancer Res; 2017 Jan; 23(2):489-502. PubMed ID: 27435400
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of adoptive transfer of expanded natural killer cells in combination with IgG1 antibody in patients with gastric or colorectal cancer.
Ishikawa T; Okayama T; Sakamoto N; Ideno M; Oka K; Enoki T; Mineno J; Yoshida N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Konishi H; Kokura S; Uno K; Naito Y; Itoh Y
Int J Cancer; 2018 Jun; 142(12):2599-2609. PubMed ID: 29388200
[TBL] [Abstract][Full Text] [Related]
17. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts.
Costa D; Venè R; Benelli R; Romairone E; Scabini S; Catellani S; Rebesco B; Mastracci L; Grillo F; Minghelli S; Loiacono F; Zocchi MR; Poggi A
Front Immunol; 2018; 9():1150. PubMed ID: 29910806
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP; Juliá EP; Rocca YS; Amat M; Bravo AI; Loza J; Coló F; Loza CM; Fabiano V; Maino M; Podhorzer A; Fainboim L; Barrio MM; Mordoh J; Levy EM
Eur J Immunol; 2015 May; 45(5):1560-9. PubMed ID: 25726929
[TBL] [Abstract][Full Text] [Related]
20. In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.
Caratelli S; Arriga R; Sconocchia T; Ottaviani A; Lanzilli G; Pastore D; Cenciarelli C; Venditti A; Del Principe MI; Lauro D; Landoni E; Du H; Savoldo B; Ferrone S; Dotti G; Sconocchia G
Int J Cancer; 2020 Jan; 146(1):236-247. PubMed ID: 31479522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]